<SEC-DOCUMENT>0001193125-18-156877.txt : 20180509
<SEC-HEADER>0001193125-18-156877.hdr.sgml : 20180509
<ACCEPTANCE-DATETIME>20180509083802
ACCESSION NUMBER:		0001193125-18-156877
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180509
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180509
DATE AS OF CHANGE:		20180509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		18816794

	BUSINESS ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d584931d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM
<FONT STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;9, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>RESTORBIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-3305277</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street, 12th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive offices, including zip code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(857) 315-5521 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;&nbsp;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of
this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2018, resTORbio, Inc. issued a press release titled &#147;resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of
Respiratory Tract Infections in the Elderly.&#148; A copy of the press release is attached as Exhibit 99.1 to this Form <FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d584931dex991.htm">Press release issued by resTORbio, Inc. on May&nbsp;9, 2018.</A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RESTORBIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: May&nbsp;9, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d584931dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g584931g34w05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio Completes Dosing of Patients in Phase 2b </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Study to Reduce the Incidence of Respiratory Tract </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Infections in the Elderly </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Topline <FONT STYLE="white-space:nowrap">16-week</FONT> data now expected in the third quarter of 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, Massachusetts, May. 9, 2018</B>&nbsp;&#150; resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people
live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that dosing has been completed in its Phase 2b trial evaluating the safety, tolerability and
efficacy of RTB101, an orally-administered, selective TORC1 inhibitor, alone or in combination with everolimus, in reducing the incidence of respiratory tract infections (RTIs) in 652 elderly subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;RTIs are a leading cause of hospitalizations and death among the elderly and are mainly caused by viruses that lack effective treatments,&#148; said
Chen Schor, President and CEO of resTORbio. &#147;Selective TORC1 inhibition has the potential to improve the function of the aging immune system and thereby reduce the incidence of RTIs, regardless of the causative pathogen, representing a new
paradigm for meeting the needs of <FONT STYLE="white-space:nowrap">at-risk</FONT> elderly patients. Increasing scientific data suggest that TORC1 inhibition also has the potential to improve the function of other aging organ systems. We are pleased
to have dosed all patients in our Phase 2b study, and we look forward to reporting topline data in the third quarter of 2018.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The randomized,
double-blind placebo-controlled Phase 2b trial was initiated to evaluate the safety, tolerability and efficacy of RTB101 alone or in combination with everolimus in reducing the incidence of RTIs. The study enrolled 652 subjects at increased risk of <FONT
STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality, defined as aged 85 and over or <FONT STYLE="white-space:nowrap">65-84</FONT> with comorbidities. The study consists of two parts during which elderly subjects were enrolled
during the winter cold and flu seasons in the southern (Part 1) and northern (Part 2) hemispheres. Part 2 of the study commenced in the U.S. in the fourth quarter of 2017 following an interim analysis of Part 1 results. Part 2 is a <FONT
STYLE="white-space:nowrap">4-arm</FONT> study comparing placebo to 10 mg of RTB101 dosed once daily (QD), 10 mg of RTB101 dosed twice daily (BID), or 10 mg of RTB101 and 0.1 mg of everolimus dosed QD. All subjects were treated with study drug for 16
weeks, followed by eight weeks of <FONT STYLE="white-space:nowrap">follow-up.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About resTORbio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of
novel therapeutics for the treatment of aging-related diseases. resTORbio&#146;s lead program is targeting the selective inhibition of TORC1 &#150; an evolutionary conserved pathway that contributes to the decline in function of multiple organ
systems, including the immune, cardiac and neurologic systems. RTB101, resTORbio&#146;s lead drug candidate, is a selective, orally administered, TORC1 inhibitor </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g584931g34w05.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently being investigated in a Phase 2b clinical trial as a first <FONT STYLE="white-space:nowrap">in-class</FONT> immunotherapy for reducing the incidence of respiratory tract infections in
the elderly by enhancing the function of the immune system. The company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without
limitation, express or implied statements or guidance regarding our plans to develop and commercialize RTB101 alone or in combination with everolimus, including the therapeutic potential and clinical benefits thereof, our ongoing and future clinical
trials for RTB101 alone or in combination with everolimus, including the timing of initiation of these trials and of the anticipated results, constitute forward-looking statements identified by words like &#147;believe,&#148; &#147;expect,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or development of RTB101, either alone or in combination with everolimus; our ability to
successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; and obtaining, maintaining and protecting our
intellectual property; as well as those risks more fully discussed in the section entitled &#147;Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed by resTORbio with the Securities and Exchange
Commission, as well as discussions of potential risks, uncertainties, and other important factors in resTORbio&#146;s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent
resTORbio&#146;s views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beth DelGiacco </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern Investor Relations, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">212-362-1200</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">beth@sternir.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Lampe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scient PR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">484-575-5040</FONT>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">michael@scientpr.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g584931g34w05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g584931g34w05.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"LKB)K:0E QVD\]17G'L'2T !S@XZT 96A#6!:R_VR8C-YIV>7C[G;I0!JT
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MX_X4@'^-H5E\)7Q8<QJ'7V((H UM-D:72K.1CEFA0D^^!0!:H YC4O\ D?\
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CSH'VL?KZT )I?A6PTV[^V%YKJ[Q@2W#[BOT]* -R@ H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
